Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-012: lenvatinib + pembrolizumab with TACE versus placebo + TACE in non-metastatic hepatocellular carcinoma
2019-002345-37Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab + lenvatinib + TACE with Placebo + TACE (2 arms). Primary endpoint: Progression-free survival. Started Jan 2020; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-002345-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002345-37.